Slide 1: AASLD Data Presentation
NASDAQ: ABUS www.arbutusbio.com November 4, 2022 AASLD Data Presentation
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: AB-729-001 Phase 1a/1b Clinical Trial
AB - 729 - 001 Phase 1a/1b Clinical Trial HBeAg : HBV E antigen | TDF: tenofovir disoproxil fumarate Part 3: Multiple Ascending Dose in cHBV Patients (n=7/cohort) E: 60mg Q4W HBV DNA - F: 60mg Q8W HBV DNA - G: 90mg Q8W + TDF HBV DNA+ I: 90mg Q8W HBV DNA - J: 90mg Q12W HBV DNA - K: 90mg Q8W HBV DNA -
Slide 4: Robust HBsAg Declines Irrespective of Dose, Dosing Schedule, HBeAg or HBV DNA Status
Robust HBsAg Declines Irrespective of Dose, Dosing Schedule, HBeAg or HBV DNA Status Mean (SE) Baseline and Δ log 10 HBsAg by Visit Data shown as mean (SE) log 10 IU/mL; HBsAg LLOQ = 0.07 IU/mL, <LLOQ defined as 0.035 IU/mL Last AB - 729 dose in Cohort K was at Week 40 *N=6; # N=5, 2 subjects did no
Slide 5: Robust HBsAg Declines Persist After Stopping AB-729
Data presented at AASLD 2022 5 Change in HBsAg vs time Robust HBsAg Declines Persist After Stopping AB - 729 33 of 41 patients had HBsAg < 100 IU/mL at some point during the trial 1 patient in Cohort E (baseline HBsAg = 583.5 IU/mL) who qualified but declined to participate in NA discontinuation ser
Slide 6: HBV Control Maintained While Off-Treatment
HBV Control Maintained While Off - Treatment Pt. 46 Pt. 51 Pt. 52 Pt. 53 Pt. 56 Pt. 58 Pt. 59 Pt. 60 Pt. 61 No patients have met virologic or clinical relapse criteria or restarted NA therapy to date HBV DNA has transiently increased in some patients and subsequently decreased with no intervention D
Slide 7: AB-729-001 Safety Summary
AE: Adverse Event | TEAE: Treatment Emergent Adverse Event 7 AB - 729 - 001 Safety Summary *1 patient (Cohort A) with rapid decline in HBsAg of ~2.0 log10 IU/mL had an unrelated Gr 2 AE of food poisoning resulting in unrelated transient Grade 3 AEs of ALT/AST elevation (without bilirubin changes) AB
Slide 8: AB-729 Key Attributes
Single trigger agent targeting all HBV transcripts Unique, proprietary GalNAc delivery technology AB - 729 Key Attributes 1.8 to 2.1 log 10 HBsAg decline in cHBV patients irrespective of dose, dosing interval or baseline characteristics Robust reduction in HBsAg with 48 weeks of treatment No evidenc
Slide 9: Clinical Collaboration with Assembly
Clinical Collaboration Provides accelerated AB - 729 combination POC with Assembly’s capsid inhibitor and a NA AB - 729 Follow Up (24 - weeks) AB - 729 (60mg) + VBR (300mg) + NA (n=32) AB - 729 + NA (n=17) VBR + NA (n=16) Baseline Wk 48 Wk 24 Primary objective: evaluate safety and tolerability of ve
Slide 10: Preliminary Phase 2a Triple Combination Data
10 Preliminary Phase 2a Triple Combination Data The proportion of patients who achieved HBsAg levels <100 IU/mL and <10 IU/mL was similar in patients who received VBR+AB - 729+NrtI and AB - 729+NrtI No patients experienced HBsAg loss or seroconversion At the time of this analysis 0/1, 2/2 (100%), an
Slide 11: 3-Pronged Approach to Therapeutic Success
Suppress Reduce Boost Viral DNA and cccDNA Pool Viral Antigen - HBsAg Host Immune System Leading to an HBV Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune respo
Slide 12: AB-101: Demonstrates Target Engagement in CD8+ Kupffer Cells in a cHBV Mouse Model
12 AB - 101: Demonstrates Target Engagement in CD8+ Kupffer Cells in a c HBV Mouse Model GalNAc - siRNA s.c. AB - 101 10 mg/kg p.o. q.d . GalNAc - siRNA s.c. AB - 101 30 mg/kg p.o. q.d . Day 0 GalNAc - siRNA s.c. Vehicle p.o. q.d . Day 0 Day 21 Day 41 AB - 101 30 mg/kg p.o. q.d . Atezolizumab 10 mg/
Slide 13: AB-101 + siRNA Combination: Increases HBV-Specific T Cell Activity and HBsAb
13 AB - 101 + siRNA Combination: Increases HBV - Specific T Cell Activity and HBsAb in Liver Liver HBV - Specific T Cells Day 42 Ex vivo Fluorospot Data presented at AASLD 2022
Slide 14: AB-101: Summary
14 AB - 101: Summary Oral small - molecule PD - L1 inhibitors have been identified which function through a novel internalization mechanism distinct from antibody approaches Combination treatment with AB - 101 and HBV - targeting siRNA resulted in the activation of HBV - specific T cell and humoral
Slide 15: Thank You
Thank You